CN112351977A - 治疗异常增殖性疾病的药剂和方法 - Google Patents

治疗异常增殖性疾病的药剂和方法 Download PDF

Info

Publication number
CN112351977A
CN112351977A CN201980025251.6A CN201980025251A CN112351977A CN 112351977 A CN112351977 A CN 112351977A CN 201980025251 A CN201980025251 A CN 201980025251A CN 112351977 A CN112351977 A CN 112351977A
Authority
CN
China
Prior art keywords
alkyl
compound
cancer
haloalkyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980025251.6A
Other languages
English (en)
Chinese (zh)
Inventor
Y·深濑
M·达根
H-G·温德尔
K·辛格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Three Institution Treatment Discovery Institute Inc
Memorial Sloan Kettering Cancer Center
Original Assignee
Three Institution Treatment Discovery Institute Inc
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Three Institution Treatment Discovery Institute Inc, Memorial Sloan Kettering Cancer Center filed Critical Three Institution Treatment Discovery Institute Inc
Publication of CN112351977A publication Critical patent/CN112351977A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C07F9/65517—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
CN201980025251.6A 2018-02-19 2019-02-18 治疗异常增殖性疾病的药剂和方法 Pending CN112351977A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862632372P 2018-02-19 2018-02-19
US62/632,372 2018-02-19
PCT/US2019/018441 WO2019161345A1 (en) 2018-02-19 2019-02-18 Agents and methods for treating dysproliferative diseases

Publications (1)

Publication Number Publication Date
CN112351977A true CN112351977A (zh) 2021-02-09

Family

ID=67619605

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980025251.6A Pending CN112351977A (zh) 2018-02-19 2019-02-18 治疗异常增殖性疾病的药剂和方法

Country Status (9)

Country Link
US (2) US12215090B2 (https=)
EP (1) EP3755693B1 (https=)
JP (1) JP2021513963A (https=)
KR (1) KR20200123184A (https=)
CN (1) CN112351977A (https=)
AU (1) AU2019221837B2 (https=)
CA (1) CA3091642A1 (https=)
IL (1) IL276639A (https=)
WO (1) WO2019161345A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113149942B (zh) * 2021-02-10 2023-06-02 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 一种洛克米兰醇酚羟基衍生物、其制备方法和应用
WO2022221519A1 (en) * 2021-04-14 2022-10-20 Memorial Sloan-Kettering Cancer Center Synthetic rocaglates with broad-spectrum antiviral activities and uses thereof
CN121712777A (zh) * 2023-08-18 2026-03-20 皇家学术促进机构麦吉尔大学 Rna解旋酶抑制剂

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011140334A2 (en) * 2010-05-06 2011-11-10 Trustees Of Boston University Compounds, methods of making or identifying compounds, and uses thereof
US20120101153A1 (en) * 2008-11-25 2012-04-26 Universite De Strasbourg Rocaglaol derivatives as cardioprotectant agents and as antineoplastic agents
US20170137400A1 (en) * 2014-07-04 2017-05-18 Pierre Fabre Medicament Flavagline derivatives

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19934952A1 (de) * 1998-07-30 2000-02-03 Novartis Ag Cyclopentabenzofuran-Derivate
AUPQ866500A0 (en) 2000-07-05 2000-08-03 Exgenix Operations Pty Ltd Therapeutic compounds and methods
US7816544B2 (en) 2004-03-23 2010-10-19 Trustees Of Boston University Synthesis of rocaglamide natural products via photochemical generation of oxidopyrylium species
DE102004024504A1 (de) 2004-05-18 2006-02-16 Bayer Healthcare Ag Neue Cylopenta[b]benzofuran-Derivate und ihre Verwendung
WO2006007634A1 (en) 2004-07-16 2006-01-26 Cerylid Biosciences Ltd Processes and intermediates
CA2652873A1 (en) 2006-05-22 2007-12-06 Trustees Of Boston University Asymmetric synthesis of rocaglamides via enantioselective photocycloaddition mediated by chiral bronsted acids
US20100168084A1 (en) 2008-05-08 2010-07-01 Huber L Julie Therapeutic compounds and related methods of use
EP2189158A1 (en) 2008-11-20 2010-05-26 DKFZ Deutsches Krebsforschungszentrum, Stiftung des Öffentlichen Rechts Combination of rocaglamide and apoptosis inducing substances for the treatment of cancer
US20140255432A1 (en) 2011-07-27 2014-09-11 Ohio State Innovation Foundation Silvestrol, silvestrol analogs and uses thereof
WO2013170257A1 (en) 2012-05-11 2013-11-14 Dana-Farber Cancer Institute, Inc. Treating muc1-expressing cancers with helicase inhibitors
WO2015085221A2 (en) 2013-12-05 2015-06-11 Memorial Sloan Kettering Cancer Center Methods for identifying anti-cancer compounds
JP6306481B2 (ja) 2014-03-17 2018-04-04 株式会社神戸製鋼所 延性及び曲げ性に優れた高強度冷延鋼板および高強度溶融亜鉛めっき鋼板、並びにそれらの製造方法
EP3888658B1 (en) * 2015-11-25 2023-12-27 Effector Therapeutics, Inc. Eif4-a-inhibiting compounds and methods related thereto
US10639378B2 (en) * 2016-06-06 2020-05-05 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120101153A1 (en) * 2008-11-25 2012-04-26 Universite De Strasbourg Rocaglaol derivatives as cardioprotectant agents and as antineoplastic agents
WO2011140334A2 (en) * 2010-05-06 2011-11-10 Trustees Of Boston University Compounds, methods of making or identifying compounds, and uses thereof
US20170137400A1 (en) * 2014-07-04 2017-05-18 Pierre Fabre Medicament Flavagline derivatives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
F I BOHNENSTENGEL 等: "1H-cyclopenta[b]benzofuran lignans from Aglaia species inhibit cell proliferation and alter cell cycle distribution in human monocytic leukemia cell lines" *
REGINA CENCIC 等: "Antitumor Activity and Mechanism of Action of the Cyclopenta[b]benzofuran, Silvestrol" *

Also Published As

Publication number Publication date
US20200392099A1 (en) 2020-12-17
US12215090B2 (en) 2025-02-04
EP3755693A4 (en) 2021-08-04
AU2019221837B2 (en) 2024-08-01
IL276639A (en) 2020-09-30
WO2019161345A1 (en) 2019-08-22
AU2019221837A1 (en) 2020-09-03
KR20200123184A (ko) 2020-10-28
CA3091642A1 (en) 2019-08-22
EP3755693A1 (en) 2020-12-30
JP2021513963A (ja) 2021-06-03
EP3755693B1 (en) 2024-06-12
US20250361218A1 (en) 2025-11-27

Similar Documents

Publication Publication Date Title
JP5714824B2 (ja) １−４−（５−シアノインドール−３−イル）ブチル−４−（２−カルバモイルベンゾフラン−５−イル）ピペラジン塩酸塩の多形相
CN101573350B (zh) 甲磺酸伊马替尼的多晶型及其制备方法以及无定形和α型的甲磺酸伊马替尼
JP4836404B2 (ja) 抗癌化合物ｚｄ１８３９の新規結晶形
US20250361218A1 (en) Agents and methods for treating dysproliferative diseases
TWI519532B (zh) （Ｒ）－７－氯－Ｎ－（啶－３－基）苯並［b］噻吩－２－羧醯胺鹽酸鹽單水合物之結晶形體
WO2023138541A1 (zh) 吡啶酰胺类parp抑制剂、及其制备方法和医药用途
WO2022100623A1 (zh) 氮取代杂环噻吩类化合物及其用途
JP2002508371A (ja) 置換されたチアゾリジンジオン誘導体、その製造方法およびその医薬的使用
JP7257328B2 (ja) ベンゾフラン誘導体遊離塩基の結晶およびその製造方法
JP2002543075A (ja) チアゾリジンジオン誘導体および抗糖尿病薬としてのその使用
KR20250048080A (ko) 나프틸아민계 미토파지 유도제의 고체 형태, 이의 제조 방법, 약학 조성물 및 용도
KR101710740B1 (ko) 2-［［［2-［(히드록시아세틸)아미노］-4-피리디닐］메틸］티오］-ｎ-［4-(트리플루오로메톡시)페닐］-3-피리딘카르복사미드의 벤젠술폰산염, 이의 결정, 이의 결정 다형 및 이들의 제조 방법
JP7531506B2 (ja) アクリル含有核輸送モジュレーターおよびその使用
US12384784B2 (en) Polymorphs of Acalabrutinib, a Bruton's tyrosine kinase inhibitor
JP2005289808A (ja) ３−置換−４−ピリミドン誘導体
CN114315830B (zh) Fxr小分子激动剂及其制备方法和用途
EA004748B1 (ru) Полиморфные формы 4-амино-6,7-диметокси-2-(5-метансульфонамидо-1,2,3,4-тетрагидроизохинолин-2-ил)-5-(2-пиридил) хиназолина и его мезилатной соли
JP5523699B2 (ja) 新規な結晶性のアトルバスタチンヘミカルシウム塩の多形相
JP7618575B2 (ja) Ｎ－（５－（（４－エチルピペラジン－１－イル）メチル）ピリジン－２－イル）－５－フルオロ－４－（３－イソプロピル－２－メチル－２ｈ－インダゾール－５－イル）ピリミジン－２－アミンおよびその塩の結晶形態および非晶質形態、ならびにその製造方法および治療的使用
EA006245B1 (ru) Гидрохлорид 4-[4-(2-пирролилкарбонил)-1-пиперазинил]-3-трифторметилбензоилгуанидина
JP2024532601A (ja) インドール化合物の固体形態、その調製方法及びその使用
WO2026064542A1 (en) 2-(tert-butoxy)-4-(3-methyl-3-(5-(methylsulfonyl)isoindolin-2-yl)butyl)phenol fumarate salts in solid forms
WO2024208266A1 (zh) 一种杂环化合物在治疗间质性肺炎中的用途
CN110194764A (zh) 酰胺类化合物、其制备方法及用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210209